Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Lip Powder Market to Reach $2,988.8 Million, Globally, by 2032 at a 6.2% CAGR: Allied Market Research




A growing need for shine-free lightweight lip color and increased awareness of cruelty-free cosmetics are anticipated to drive the growth of the global lip powder market during the forecast period. The Asia-Pacific region is projected to hold the majority of market share by 2032.

PORTLAND, Ore., Sept. 7, 2023 /PRNewswire/ — Allied Market Research has recently published a report, titled,Lip Powder Market by Type (Lip Powder Palettes, Lip Powder Pen), by End User (Under 18 Years Old, 18-30 Years Old, 30-45 Years Old, Above 45 Years Old), by Distribution Channel (Online, Offline): Global Opportunity Analysis and Industry Forecast, 2023-2032″. According to the report, the global lip powder market generated $1,689.8 million in 2022, and is anticipated to generate $2,988.8 million by 2032, witnessing a CAGR of 6.2% from 2023 to 2032.

Request Sample Copy of the Report:

Prime Determinants of Growth

The growing demand for natural and organic beauty products is expected to drive the growth of the global lip powder market in the forecast period from 2023 to 2032. However, the application of lip powder requires a specific amount of skill and practice, which may hamper the lip powder market growth in the coming future. On the contrary, a rise in consciousness about appearance among working-class females is expected to offer remunerative opportunities for the expansion of the lip powder market during the forecast period.

Report Coverage & Details:

Report Coverage


Forecast Period


Base Year


Market Size in 2022

$1,689.8 million

Market Size in 2032

$2,988.8 million


6.2 %

No. of Pages in Report


Segments covered

Type, End User, Distribution Channel, and Region


Rising willingness among customers to try out new cosmetics products


Significantly growing corporate sector in developing nations



The rapid growth of social media platforms which increases the global sales of beauty products


Capitalizing on the growing demand for new lip products



Lip powder might not be suitable for all skin types


COVID-19 Scenario

  • The outbreak of the COVID-19 pandemic has had a significant impact on the growth of the global lip powder market. The pandemic slowed worldwide industry growth, creating widespread disruption for both customers and sellers. Global markets and production facilities were closed, which halted the development, distribution, and marketing of cosmetics.
  • However, during lockdowns and social isolation measures, e-commerce increased in significance at an unprecedented pace, which allowed the lip powder market to continue operating despite the closure of traditional retail sites.
  • Moreover, in the post-pandemic period, there has been an increasing need for simple, versatile, and clean cosmetics that cater to changing customer needs.

Procure Complete Report (300 Pages PDF with Insights, Charts, Tables, and Figures):

Type: Lip Powder Palettes Sub-segment to Hold Highest Share by 2032

The lip powder palettes sub-segment of the global lip powder market accounted for the largest share of 56.2% in 2022 and is expected to witness significant growth during the forecast period. The prominent growth of the sub-segment is mainly because these palettes offer a dynamic and varied option for customers who wish to be creative with different lip styles. They offer an affordable means to create new lip appearances for different events by combining multiple shades in a single compact.

End User: 30-45 Years Old Sub-segment to Hold Majority of Market Share by 2032

The 30-45 years old sub-segment of the lip powder market accounted for the highest share of 41.0% in 2022 and is projected to continue to hold major share during the forecast period. The prominent growth of the sub-segment is mainly because the 30-45 age old group has hectic schedules, and the convenience of applying lip powder fits perfectly with their on-the-go habits. Furthermore, the adaptability of lip powder allows people to achieve an array of looks, ranging from a pastel tint to a stronger hue, allowing them to match their style on different occasions.

Distribution Channel: Online Sub-segment to Hold Majority of Market Share by 2032

The online sub-segment of the global lip powder market accounted for the largest share of 51.7% in 2022 and is predicted to grow at the highest CAGR of 6.6% by 2032. The prominent growth of the sub-segment is mainly because online distribution channels are increasingly popular in the lip powder market as individuals prefer e-commerce sites for their shopping needs.

Region: Asia-Pacific Market to Grab Highest Share by 2032

The lip powder market in the Asia-Pacific region accounted for the highest share of 40.5% in 2022 and is likely to dominate during the forecast period. This growth is mainly because of increased concerns about looks among working females in this region. Additionally, increased spending on personal grooming items in developing nations such as South Korea, China, Indonesia, India, the Philippines, Malaysia, and Taiwan is pushing up the demand for cosmetic products. Furthermore, creative and appealing packaging is likely to expand the market’s client base in this region.

Enquire before buying:

Leading Players in the Lip Powder Market:

  • The Estee Lauder Companies, Inc.
  • buxom cosmetics
  • Chanel International B.V.
  • Revlon
  • Sephora
  • by terry
  • L’Oreal
  • Clinique
  • Shiseido Company, Limited

The report provides a detailed analysis of the key players of the global lip powder market. These players have adopted different strategies, such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain their dominance in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

Country Reports We Have in this Industry:

Canada Lip Powder Market Opportunity Analysis and Industry Forecast, 2022-2032
U.S. Lip Powder Market Opportunity Analysis and Industry Forecast, 2022-2032
Mexico Lip Powder Market Opportunity Analysis and Industry Forecast, 2022-2032
Europe Lip Powder Market Opportunity Analysis and Industry Forecast, 2022-2032
UK Lip Powder Market Opportunity Analysis and Industry Forecast, 2022-2032

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.


David correa
United States
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int’l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
[email protected] 

Logo – 

Cision View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading